This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.
Study Type
OBSERVATIONAL
Enrollment
50
The University of Kansas Medical Center
Kansas City, Kansas, United States
RECRUITINGBody weight
Assess changes in body weight by measuring weight on a calibrated scale
Time frame: Baseline through 6-month visit
Body composition
Assess changes in lean and fat mass and fat-free mass in kilograms by total body DXA scan
Time frame: Baseline through 6-month visit
Bone mineral density (BMD)
Assess changes in bone mineral density (BMD) by completing femur DXA scans
Time frame: Baseline through 6-month visit
Muscle function
Assess muscle function changes in pounds by completing Grip strength tests
Time frame: Baseline through 6-month visit
Muscle function
Assess changes to muscle function by the number of repetitions achieved per 30-second Sit-to-stand test
Time frame: Baseline through 6-month visit
Estrogen level role in BMD changes during GLP-1RA therapy
Examine the moderating role of estrogen levels on changes in bone mineral density (BMD) during GLP-1RA therapy.
Time frame: Baseline through 6-month visit
Estrogen level role in muscle function changes during GLP-1RA therapy
Examine the moderating role of estrogen levels on changes in muscle function during GLP-1RA therapy.
Time frame: Baseline through 6-month visit
Diet intake
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Examine changes in dietary intake including protein consumption by collecting 24-hrs diet recalls.
Time frame: Baseline through 6-month visit
Diet quality
Examine changes in dietary quality by collecting 24-hrs diet recalls.
Time frame: Baseline through 6-month visit